GAITHERSBURG, Md., Oct. 11, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, will present study findings during two ...

Novavax, Inc. (NASDAQ: NVAX) ranks among the most oversold biotech stocks to invest in. Novavax, Inc. (NASDAQ:NVAX) announced ...

Novavax, Inc. recently announced at the Jefferies London Healthcare Conference 2025 that it is shifting its focus from direct COVID-19 commercial operations to an expanded research and development ...

Prosper Junior Bakiny is a contributing Motley Fool healthcare analyst covering biotechnology, pharmaceuticals, and healthcare stocks. Before The Motley Fool, Prosper wrote about investing topics ...

Moderna’s sales soared into the billions as it conquered the coronavirus vaccine market -- and today the company promises to deliver many new products in the near term. Novavax struggled in recent ...

Novavax, Inc.'s Sanofi partnership provides much-needed financial support via upfront and milestone payments, stabilizing its finances. Combination vaccines are set to be an essential market, but ...

Five years ago, Novavax (NASDAQ: NVAX) was a little-known clinical-stage biotech whose leading pipeline candidate was an influenza vaccine. Then came the pandemic. The company quickly grew in ...

Novavax (NVAX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

A third COVID-19 vaccine, made by Novavax, will soon be available in pharmacies and doctor's offices. The Food and Drug Administration Tuesday authorized use of the Novavax vaccine, which is based on ...

On Oct. 3, the Food and Drug Administration (FDA) authorized the updated COVID-19 vaccine by Novavax for people ages 12 and older. The Centers for Disease Control and Prevention and its advisory panel ...

Bullish option flow detected in Novavax (NVAX) with 4,713 calls trading, 1.1x expected, and implied vol increasing almost 10 points to 67.16%.